RNAI-MEDIATED INHIBITION OF OCULAR HYPERTENSION TARGETS

/Home/Lyophilization and Protein Formulation Patents/Patents - Biologics/European Patents - Biologics

RNAI-MEDIATED INHIBITION OF OCULAR HYPERTENSION TARGETS
Publication number: WO2006084217
Publication date: 2006-08-10
Inventor: SHEPARD ALLAN R (US); CHATTERTON JON E (US); CLARK ABBOT F (US)
Applicant: ALCON INC (CH); SHEPARD ALLAN R (US); CHATTERTON JON E (US); CLARK ABBOT F (US)
Classification:
- international: C12N15/11; A61K31/713; C12N15/11; A61K31/713;
- european:
Application number: WO2006US04018 20060201
Priority number(s): US20050648926P 20050201; US20050753364P 20051222
Abstract of WO2006084217

RNA interference is provided for inhibition of ocular hypertension target mRNA expression for lowering elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Ocular hypertension targets include carbonic anhydrase II, IV, and XII; 1- and 2 adrenergic receptors; acetylcholinesterase; Na+/K+-ATPase; and Na-K-2Cl cotransporter. Ocular hypertension is treated by administering interfering RNAs of the present invention.